Background. Escherichia coli sequence type ST131 (O25:H4), associated with the CTX-M-15 extended-spectrum b-lactamase, has emerged internationally as a multidrug-resistant pathogen but has received little attention in the United States.
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31 (91) 18 (72) 6 (18) 0 (0) by guest on November 6, 2016 http://cid.oxfordjournals.org/ Downloaded from historical antimicrobial-resistant E. coli strains, E. coli ST131 derives from (virulence-associated) phylogenetic group B2. CTX-M-encoding genes are embedded in transposon-like structures, often carried in plasmids containing additional resistance genes [5] . Acquisition of these elements, which encode multiple antimicrobial resistance mechanisms, can confer resistance to b-lactams, fluoroquinolones, aminoglycosides, and trimethoprim-sulfamethoxazole. However, high-level fluoroquinolone resistance usually also involves multiple point mutations within the "quinolone resistance-determining region" of gyrA (DNA gyrase) and parC (topoisomerase), which encode the targets of fluoroquinolones. Such mutations arise spontaneously, then are transmitted vertically.
Because of the increasing prevalence in E. coli of resistance to fluoroquinolones and extended-spectrum cephalosporins, evidence of CTX-M-15-positive E. coli in the United States [12, 13] , and sporadic reports of serious E. coli ST131 infections in the United States [14, 15] , we hypothesized that ST131 may now be contributing importantly to antimicrobial-resistant E. coli infections nationwide. Accordingly, using a nationally representative sample of clinical E. coli isolates from 2007, we assessed ST131's current prevalence and contribution to the US antimicrobial-resistant E. coli population. In addition, to gain insights into the basis for ST131's emergence, we studied ST131's association with CTX-M-15 (vs. other ESBLs) and its virulence characteristics, fluoroquinolone resistance genetics, and clonal composition.
METHODS

Strains.
During 2007, the SENTRY and Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Antimicrobial Surveillance Programs collected 1596 nonduplicate E. coli clinical isolates from patients hospitalized in 33 widely distributed US medical centers [13] . Of the 1596 isolates, 118 (7.4%) exhibited reduced broth microdilution susceptibility to extendedspectrum cephalosporins [16] and so were defined as ESBL positive. The 118 ESBL-positive isolates were tested by polymerase chain reaction (PCR) for bla CTX-M genes, and amplicons were sequenced and analyzed [13] . Three control groups (ie, subsets 2-4) were selected. For subset 2, all non-CTX-M-15, ESBL-positive isolates that were available for molecular analysis (n p 25) were used. For subsets 3 and 4 (non-ESBL; fluoroquinolone resistant and fluoroquinolone susceptible, respectively), representatives were chosen randomly from among the available isolates from a particular city to equal the number of subset 1 isolates from that city. Susceptibility testing. Coresistance was assessed by broth microdilution and/or disk diffusion according to procedures and interpretive criteria specified by the Clinical Laboratory Standards Institute [13, 16, 17] . Intermediate susceptibility was analyzed as resistance. Multidrug-resistant (MDR) isolates were those resistant to at least 1 representative of у3 antimicrobial classes, including b-lactam/b-lactamase inhibitors (piperacillin-tazobactam), extended-spectrum cephalosporins (ceftriaxone, ceftazidime, cefepime), aminoglycosides (gentamicin, tobramycin), fluoroquinolones (ciprofloxacin), and trimethoprim-sulfamethoxazole. The resistance score was the number of agents to which resistance was evident.
Molecular methods. E. coli phylogenetic group (A, B1, B2, and D) was determined by PCR [18] . Group B2 isolates were assessed for ST131 status by O25b rfb detection [7] , random amplified polymorphic DNA profiling [10] , and detection of ST131-specific single-nucleotide polymorphisms (SNPs) in mdh and gyrB [10] . Selected putative ST131 isolates underwent confirmatory multilocus sequence typing on the basis of partial sequence for adk, fumC, gyrB, icd, mdh, purA, and recA (http://mlst.ucc.ie) [10] , which uniformly confirmed their ST131 status. Presence of 62 extraintestinal virulence genes was assessed by multiplex PCR [10, 19, 20] . The virulence score was the number of virulence genes detected, adjusted for multiple detection of certain operons (ie, pap [P fimbriae], sfa/foc [S and F1C fimbriae], and kps [group 2 capsule]). For selected isolates, SNPs within the quinolone resistance-determining region of gyrA and parC were identified by sequence analysis [21] , in comparison with strains MG1655 [22] and H17 (a fluoroquinolone-susceptible, virulence gene-deficient ST131 urosepsis isolate from 1985) [20] .
XbaI pulsed-field gel electrophoresis (PFGE) analysis was used for pulsotype assignment (on the basis of a 94% Dice similarity coefficient threshold) and dendrogram construction [23] . Profiles also were compared with a private reference library containing 150 pulsotypes, from 275 ST131 isolates (J.R.J., unpublished data).
Statistical analyses. Comparisons of proportions and scores were tested using the Fisher exact test and the MannWhitney U test, respectively. (Alternate methods that account for by-locale clustering-that is, linear mixed-model regression and logistic generalized estimating equations, gave essentially identical results.) Principal coordinates analysis, a multidimensional scaling method analogous to principle components analysis, was used to collapse the molecular dataset for simplified between-group comparisons [24] . Groups were compared on each of the first 3 coordinates, which capture most of the variance within the dataset, using a 2-tailed t test.
RESULTS
Source, phylogenetic distribution, and ST131 prevalence.
The 127 systematically selected E. coli clinical isolates from the SENTRY and MYSTIC collections (United States, 2007) were from bloodstream (73%); wounds, abscesses, tissue, or bone (15%); respiratory samples (9%); and miscellaneous sources (2%). Phylogenetic group B2 predominated within each resistance subset, accounting for 150% of isolates in subsets 1, 3, and 4 and a plurality of those in subset 2 (Table 1) . ST131 accounted for 54 (70%) of the 77 total group B2 isolates but was strikingly distributed by subset, accounting for nearly all group B2 isolates within subsets 1-3 but none within subset 4 (P ! .001) ( Table 1) . Accordingly, ST131 was significantly associated with bla CTX-M-15 among ESBL-positive isolates (subsets 1 and 2) and with fluoroquinolone resistance among ESBLnegative isolates (subsets 3 and 4). ST131 and non-ST131 isolates were distributed similarly by specimen type. On the basis of the prevalence of ST131 within each subset (Table 1) and each subset's prevalence within the source SENTRY and MYS-TIC collections, the estimated overall prevalence of ST131 within the source collections was 16.6%.
Antimicrobial resistance. Overall, resistance to antimicrobial agents other than those that defined the 4 subsets was common and varied significantly by subset (Table 1) . Among ESBL-positive isolates (subsets 1 and 2), subset 1 isolates (bla CTX-M-15 positive) were significantly more likely than subset 2 isolates (bla CTX-M-15 negative) to be fluoroquinolone resistant, extended-spectrum cephalosporin resistant, or aminoglycoside resistant; similar trends were obtained for most other resistance phenotypes (Table 1) . Likewise, among ESBL-negative isolates (subsets 3 and 4), subset 3 isolates (fluoroquinolone resistant) were significantly more likely than subset 4 isolates (fluoroquinolone susceptible) to be trimethoprim-sulfamethoxazole 
.001 .001 resistant, aminoglycoside resistant, dually trimethoprim-sulfamethoxazole and fluoroquinolone resistant, resistant to any drug class, or MDR (Table 1) . Aggregate resistance scores were highest in subset 1 (median score, 6) and decreased progressively through subsets 2, 3, and 4 (median scores, 4, 2, and 0, respectively) ( Table 2) . Within subsets 1-3 the ST131 and non-ST131 isolates did not differ significantly for the prevalence of any phenotype excepting aminoglycoside resistance and "any resistance," which within subset 2 were significantly more prevalent among ST131 isolates (ie, for aminoglycoside resistance, 7 (Table 2) .
On the basis of the proportional contribution of ST131 to specific resistance phenotypes within each subset and each subset's contribution to the source population, the net contribution of ST131 to various resistant subpopulations with the source SENTRY and MYSTIC collections was calculated (Table 3) . According to these estimates, ST131 accounted for 140% of all isolates exhibiting any resistance; 150% of aminoglycoside-resistant, MDR, and fluoroquinolone plus trimethoprim-sulfamethoxazole-resistant isolates; and 67%-69% of extendedspectrum cephalosporin-resistant and fluoroquinolone-resistant isolates. Virulence traits. To identify possible explanations for ST131's remarkably high prevalence, especially among antimicrobial-resistant strains, phylogenetic background and virulence profiles were examined. The ST131 isolates exhibited a significantly greater prevalence of group B2 (100%) than did the non-ST131 isolates within any subset, including group B2-dominated subset 4 (P ! .001 for each comparison) (Table 4) . Likewise, according to the first 3 coordinates of a principle coordinates analysis on the basis of all 62 studied virulence genes, the ST131 isolates exhibited highly distinctive virulence profiles that significantly differentiated them from non-ST131 isolates, whether these were considered collectively (P ! .001: coordinate 1 only) or by individual subset (P ! .01 for 2 or 3 coordinates per comparison). In a plot of the coordinate 1-coordinate 2 plane, which captured 66% of total variance, the ST131 isolates clustered tightly in the lower left quadrant, clearly separated from the non-ST131 isolates (Figure 1) .
The basis for these aggregate virulence profile differences was explored through univariate comparisons that involved individual virulence genes. Thirteen virulence traits were significantly more prevalent among the 54 total ST131 isolates than among the non-ST131 isolates within at least 1 of the 4 subsets, whereas 11 virulence traits were significantly more prevalent among the non-ST131 isolates (subset 4 only) ( Table 4) . Accordingly, aggregate virulence scores among the combined ST131 isolates were significantly higher than among the non-ST131 subset 1-3 isolates and were only slightly (and nonsignificantly) lower than among the subset 4 isolates (Table 5) .
PFGE analysis. To clarify the relationship of ST131 to other E. coli and to identify additional explanations for ST131's prominence, PFGE was used to assess (1) genomic diversity among ST131 and non-ST131 isolates, (2) the clonal distribution of bla CTX-M-15 , and (3) the geographic distribution of ST131-associated pulsotypes. Consistent with their common genetic background, ST131 isolates exhibited more homogeneous PFGE profiles than did non-ST131 isolates (Figure 2 ). For example, in the PFGE-based dendrogram the ST131 cluster extended to 76% similarity versus 45% overall. Likewise, compared with non-ST131 isolates, ST131 isolates were significantly more likely to exhibit the same pulsotype (59% vs 20%; P ! .001) or frankly indistinguishable profiles (15% vs 3%; P p .04).
Among the ST131 isolates, bla CTX-M-15 positivity was concentrated within specific subclusters, suggesting vertical transmission (Figure 2 ). However, several highly similar isolates were bla CTX-M-15 discordant, suggesting horizontal gene transfer or gene loss. ST131 was encountered in 14 of the 17 study locales. Within each of the 6 ST131-associated pulsotypes that included у3 isolates, multiple locales were represented; one 5-isolate pulsotype actually spanned 5 distinct locales.
gyrA and parC. Sequence analysis of the quinolone resis- All 14 fluoroquinolone-resistant ST131 isolates (excepting 1 with an obviously recombined parC) exhibited identical sequence across both genes, including 4 conserved nonsynonymous SNPs, 2 each in gyrA (c248t and g259a) and parC (g239t and a251t). The first 3 of these nonsynonymous SNPs were also present in all 7 fluoroquinolone-resistant non-ST131 isolates (which exhibited diverse phylogenetic backgrounds), whereas the fourth SNP was ST131 specific. A fifth non-synonymous SNP, gyrA g166a, occurred in a single fluoroquinolone-resistant non-ST131 isolate. In contrast, multiple synonymous (ie, silent) SNPs differentiated ST131 isolates from non-ST131 isolates and distinguished among the various non-ST131 isolates. The historical fluoroquinolone-susceptible ST131 isolate exhibited identical gyrA and parC sequence to the present fluoroquinolone-resistant ST131 isolates except for the 4 conserved nonsynonymous SNPs and a single synonymous SNP (c321g) in parC.
DISCUSSION
Our analysis of 127 systematically selected E. coli isolates from the nationally representative SENTRY and MYSTIC surveillance programs (United States, 2007) found that a single E. coli clonal group, ST131, was highly prevalent, particularly among antimicrobial-resistant isolates. By extrapolation, we estimated that within the source collections ST131 accounted for (1) ∼17% of isolates overall, (2) 44% of antimicrobial-resistant isolates, (3) 150% of MDR isolates and those dually resistant to fluoroquinolones and trimethoprim-sulfamethoxazole, and (4) 67%-69% of those resistant to fluoroquinolones or extendedspectrum cephalosporins. These remarkably high prevalence values are unprecedented within E. coli, which is a highly diverse species that in clinical collections is usually represented by multiple minority clonal groups [25, 26] . This suggests that ST131 has emerged as an important, new, disseminated MDR extraintestinal pathogen.
The clinical and public health implications of the observed high prevalence of ST131, a pathogen with the ability to cause serious or fatal extraintestinal infections [14, 15] , are potentially profound. Because fluoroquinolones are increasingly relied on for empirical therapy of urinary tract infections [2, 27] , fluoroquinolone resistance in E. coli poses a substantial threat among ambulatory patients, increasing the risk of treatment failure despite use of what traditionally has been a predictably effective regimen. Dual fluoroquinolone and trimethoprim-sulfamethoxazole resistance is even more problematical, eliminating both current mainstays for empirical oral urinary tract infection therapy [27] . Both MDR status and resistance to extended-spectrum cephalosporins also threaten hospitalized patients, for whom extended-spectrum cephalosporins and other antimicrobials, such as aminoglycosides and b-lactam/b-lactamase inhibitors, constitute standard empirical therapy.
The estimated overall contribution of ST131 to these important phenotypes (ie, 67%-69% of fluoroquinolone or extended-spectrum cephalosporin resistance, 55% of combined fluoroquinolone and trimethoprim-sulfamethoxazole resistance, and 52% of MDR isolates) suggests that as of 2007 ST131 had become the major cause of significantly antimicrobial-resistant E. coli infections in the United States. By extension, the emergence of ST131 is likely the main explanation for recent increases in antimicrobial resistance prevalence in E. coli, with the resulting adverse consequences for clinical outcomes and costs. Our findings suggest possible explanations for ST131's remarkable success as an emerging pathogen, including phylogenetic background, virulence characteristics, and antimicrobial resistance capability. ST131 is from phylogenetic group B2, which is associated epidemiologically and experimentally with extraintestinal virulence [28, 29] . Although much of its enhanced virulence potential is due to defined virulence traits, undefined group B2-associated qualities also likely contribute. Because the ST131 isolates were significantly more likely to be from group B2 than were the non-ST131 isolates, they may have a fitness advantage because of their group B2 genomic backbone, independent of accessory traits.
In addition, the ST131 isolates significantly exceeded the non-ST131 isolates for extent of resistance and/or virulence profiles. According to individual traits and aggregate scores, compared with resistant non-ST131 isolates (from subsets 1-3), the ST131 isolates were as or more antimicrobial resistant and significantly more virulent appearing. Likewise, compared with susceptible non-ST131 isolates (from subset 4) the ST131 isolates were approximately as virulent appearing but significantly more antimicrobial resistant. Thus, ST131 appears to combine resistance and virulence, which in E. coli traditionally have been somewhat mutually exclusive [30] . This resistanceplus-virulence combination may give ST131 a competitive advantage over other E. coli, promoting its clonal expansion and dominance within niches traditionally occupied by less virulent and/or more susceptible clones.
Our findings provide other insights into ST131's current predominance among antimicrobial-resistant E. coli. Sequence analysis of gyrA and parC, which encode the drug targets of fluoroquinolones [21] , suggested that current fluoroquinoloneresistant ST131 isolates derive from a recent common fluoroquinolone-resistant ST131 ancestor, which in turn descended from an earlier (perhaps in the 1980s) fluoroquinolone-susceptible progenitor by accumulating 4 nonsynonymous SNPs within gyrA and parC. Likewise, during this same interval the ST131 ancestor apparently acquired the characteristic suite of ST131-associated virulence genes, which are fairly uniformly present among current (fluoroquinolone-resistant) ST131 isolates but are largely absent from the historical fluoroquinolonesusceptible ST131 reference strain. In contrast, bla CTX-M-15 seemingly entered ST131 more recently, likely by horizontal transfer of a mobile genetic element into у1 already fluoroquinoloneresistant ST131 lineages.
Layered on this postulated evolutionary scenario is the apparent widespread distribution of ST131 pulsotypes among locales [6, 8] , likely reflecting ongoing dissemination of ST131, another probable contributor to ST131's emergence. Although ST131's historical acquisition of fluoroquinolone resistance, bla CTX-M-15 (and other resistance elements), and virulence genes represents a fait accompli, ongoing spread of ST131 suggests the possibility of identifying transmission pathways and reservoirs to interrupt further dissemination. Investigation is urgently needed into the sources of ST131 (including, possibly, certain human groups, food animals, and/or companion animals) and the factors contributing to ST131's widespread dissemination (including, possibly, host-to-host or foodborne transmission vs environmental contamination). On the basis of the findings of such studies, appropriate public health interventions (to block transmission) and interventions toward more parsimonious antimicrobial use (to decrease selection pressure) should be aggressively pursued to curtail further emergence of this threatening pathogen.
In summary, we found that among the SENTRY and MYS-TIC programs' US E. coli isolates (2007), ST131 accounted for an estimated 17% of the isolates overall but for 52% of isolates resistant to у3 antimicrobial classes, 55% of those dually resistant to fluoroquinolones and trimethoprim-sulfamethoxazole, and 67%-69% of those resistant to extended-spectrum cephalosporins or fluoroquinolones. Although bla CTX-M-15 was concentrated within specific lineages, implying recent acquisition, 4 distinctive fluoroquinolone resistance-associated gyrA and parC SNPs were ubiquitous within ST131, indicating that they antedate ST131's recent expansion. ST131's distinctive combination of resistance and virulence, plus widespread dissemination among locales, may underlie its epidemiologic success. These findings establish ST131 as a major drug-resistant pathogen in the United States and, consequently, an important new public health threat in need of urgent investigation and remediation efforts.
